tbuckley/cabot-search huggingface dataset:
Erythropoiesis Stimulating Agents (ESA) for the Treatment of Chemotherapy Induced Anemia in Patients with Hemoglobin Levels (Hb) &amp;lt;11g/Dl- a Systematic Review and Meta-Analysis
Authors: Luciano Paladini, Otavio Clark, Luciana Clark, Tobias Engel, Eneas Faleiros
Journal: Blood (2008)
IL-2 + Anti-IL2 Complex in Situ Stimulation of Host Tregs Combined with Absence of Donor B7.1 / B7.2: A Novel Approach to Facilitate Chimerism in RIC MHC-Matched Miha-Mismatched BMT Recipients.
Authors: Monica Jones, Alwi Shatry, Bruce R. Blazar, Robert B. Levy
Journal: Blood (2009)
Preclinical Evaluation of a Novel Non-Invasive Epicutaneous Vaccine Against Respiratory Syncytial Virus
Authors: Pierre-Louis Hervé, Delphyne Descamps, Charlotte Deloizy, Véronique Dhelft, Daphné Laubreton, Edwige Bouguyon, Pierre-Henri Benhamou, Hugh A. Sampson, Jean-François Eléouët, Nicolas Bertho, Lucie Mondoulet, Sabine Riffault
Journal: Journal of Allergy and Clinical Immunology (2017)
Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma
Journal: American Journal of Respiratory and Critical Care Medicine (2006)

Asthma treatment guidelines recommend addition of controller medications for patients with poorly controlled asthma. We compared the effectiveness of once-daily oral controller therapy with either an antileukotriene receptor antagonist (montelukast) or low-dose theophylline added to existing medications in patients with poorly controlled asthma.We conducted a randomized, double-masked, placebo-controlled trial in 489 participants with poorly controlled asthma randomly assigned to placebo, theophylline (300 mg/d), or montelukast (10 mg/d). Participants were monitored for 24 wk to measure the rate of episodes of poor asthma control (EPACs) defined by decreased peak flow, increased beta-agonist use, increased oral corticosteroid use, or unscheduled health care visits.There was no significant difference in EPAC rates (events/person/yr) compared with placebo: low-dose theophylline, 4.9 (95% confidence interval [CI], 3.6-6.7; not significant); montelukast, 4.0 (95% CI, 3.0-5.4; not significant); and placebo, 4.9 (95% CI, 3.8-6.4). Both montelukast and theophylline caused small improvements in prebronchodilator FEV(1) of borderline significance. Nausea was more common with theophylline only during the first 4 wk of treatment. Neither treatment improved asthma symptoms or quality of life. However, in patients not receiving inhaled corticosteroids, addition of low-dose theophylline significantly (p < 0.002) improved asthma control and symptoms as well as lung function.Neither montelukast nor low-dose theophylline lowered the EPAC rate of poor asthma control in patients with poorly controlled asthma despite improved lung function. For patients not using inhaled corticosteroids, low-dose theophylline improved asthma symptom control more than montelukast or placebo, and provides a safe and low-cost alternative asthma treatment.
Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial
Authors: E. Lopci, P. Zucali, G. Ceresoli, A. Testori, E. Voulaz, K. Marzo, L. Leonardi, M. Rodari, L. Olivari, M. Perrino, G. Ferraroli, E. Bottoni, A. Crepaldi, A. Galeassi, L. Gurrieri, G. Veronesi, M. Alloisio, A. Santoro, A. Chiti
Journal: Annals of Oncology (2016)
SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours
Authors: N. Zilembo, L. Giannetta, L. Crinò, A. Bearz, D. Amoroso, T. Gamucci, M. Buscaglia, M. Tiseo, V. Soldatenkova, N. Chouaki, H. Depenbrock, F.R. Hirsch, L. Paz-Ares, P. Bidoli
Journal: Annals of Oncology (2016)
Nanoporous Materials: Synthetic vs Natural: Diatoms Bioderived Porous Materials for the Next Generation of Healthcare Nanodevices (Adv. Healthcare Mater. 3/2017)
Authors: Ilaria Rea, Monica Terracciano, Luca De Stefano
Journal: Advanced Healthcare Materials (2017)

Low cost and large available biogenic silica from diatoms and diatomaceous earths represents an innovative material for successful development of next generation healthcare devices, overcoming the limitation of synthetic inorganic and polymeric materials production. This is demonstrated by Luca De Stefano and co-workers in article 1601125. The cover picture shows some examples of bioengineered nature-derived silica nanodevices with biomedical functionalities for biosensing and subcellular drug delivery applications.
Low and High Dose Peanut Oral Immunotherapy (OIT) Similarly Suppress Th2 Cytokine and Basophil Activation Responses
Authors: Xiaohong Yue, Michael D. Kulis, Huamei Zhang, Rishu Guo, Kelly Orgel, Edwin Kim, A. Wesley Burks, Brian P. Vickery
Journal: Journal of Allergy and Clinical Immunology (2017)
Eosinophilic Esophagitis Risk Variant at 2p23 Dampens IL-13-Induced Calpain-14 Promoter Activity in a STAT6-Dependent Manner
Authors: Leah Claire Kottyan, Daniel E. Miller, Avery Maddox, Arthur Lynch, Connor Schroeder, Josh Lee, Michael Brusilovsky, Matthew T. Weirauch, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2017)
Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia.
Authors: Michael Andreeff, Michael Fiegl, Marina Konopleva, Borys Korchin, Kumar Kaluarachchi, William G. Bornmann, Patrick H. Guthrie, Romain Harmancey, Heinrich Taegtmeyer, Ismael J. Samudio
Journal: Blood (2009)
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer
Authors: M.H. Huber, S.M. Lippman, S.E. Benner, M. Shirinian, I.W. Dimery, C.L. Earley, R.J. Winn, J. Brooks, L. Baez, W.K. Hong
Journal: Annals of Oncology (1995)
Survey of Qol (quality of life) on Patients Receiving Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Korean CML Working Party Group
Authors: Kyoung Ha Kim, Dae-Young Kim, Sung-Hyun Kim, Yeo-Kyeoung Kim, Inho Kim, Hee-Jin Kim, Sang Kyun Sohn, Jeon-Ok Lee, June-Won Cheong, Chul Won Jung, Young-Uk Cho
Journal: Blood (2015)
Metabolic Tumor Volume Is an Independent Prognosis Factor Predicting patient's Outcome in Hodgkin Lymphoma
Authors: Salim Kanoun, Cedric Rossi, Alina Berriolo-Riedinger, Olivier Humbert, Inna Dygay-Cochet, Marie-Lorraine Chretien, Caroline Legouge, Louis Berthet, Jean-Noel Bastie, Rene-Olivier Casasnovas
Journal: Blood (2012)
Drug Delivery: Zero-Order Antibiotic Release from Multilayer Contact Lenses: Nonuniform Drug and Diffusivity Distributions Produce Constant-Rate Drug Delivery (Adv. Healthcare Mater. 3/2017)
Authors: Gustavo Guzman, Siamak Shams Es-haghi, Turgut Nugay, Mukerrem Cakmak
Journal: Advanced Healthcare Materials (2017)

In article 1600775, Mukerrem Cakmak and co-workers present a novel approach to zero-order constant-rate drug delivery from three-layer bimodal amphiphilic conetwork contact lenses. Combined effects of nonuniform distribution of drug loading and diffusion constants maintains low local drug concentration at the lens–fluid interface and yields zero-order drug delivery. The release rates of topical antibiotics provide constant-rate therapeutic-level delivery with appropriate oxygen permeability for at least 30 h.
METB-03. DISABLED CELL DENSITY SENSING BY TUMOR SUPPRESSORS LEADS TO DYSREGULATED CHOLESTEROL SYNTHESIS IN GLIOBLASTOMA
Authors: Diane Kambach, A. Gesine Cauer, Carlos Tristan, Orieta Celiku, Uma Shankavaram, Eric Batchelor, Jayne M. Stommel
Journal: Neuro-Oncology (2016)

A hallmark of cellular transformation is the evasion of contact-dependent inhibition of growth. To find new therapeutic targets for glioblastoma, we looked for pathways that are inhibited by high cell density in normal astrocytes but have lost this regulation in glioma cells. Here we report that at high cell density, normal astrocytes turn off cholesterol synthesis but glioma cells keep this pathway on. Correspondingly, cholesterol pathway upregulation correlates with poor prognosis for glioblastoma patients. Densely-plated glioma cells increase oxygen consumption to synthesize cholesterol, resulting in a decrease in mitochondrial respiration but without a compensating increase in aerobic glycolysis. We also show that constitutive cholesterol synthesis can be turned off by CDK inhibitors and correlates with disabled cell cycle control though loss of p53 and RB. Finally, glioma cells, but not astrocytes, are sensitive to CYP51 inhibition, suggesting that specifically targeting cholesterol synthesis might be an effective treatment for glioblastoma.
420P Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors- retrospective multi-center study in Taiwan
Authors: C.-T. Liu, L.-T. Chen, Y.-Y. Chen, J.-S. Chen, Y.-L. Su, W.-C. Chou, C.-H. Lu, F.-C. Ku, M.-H. Chen, Y.-S. Shan
Journal: Annals of Oncology (2016)
Bortezomib Is Effective for Down Regulation of Gene Transcriptions Specifically Expressed in Clonogenic Myeloma Side Population Cells
Authors: Miho Nara, Hiroyuki Tagawa, Kazuaki Teshima, Atsushi Watanabe, Mitsugu Ito, Atsushi Kitabayashi, Masaaki Kume, Yoshiaki Hatano, Shinsuke Iida, Kenichi Sawada
Journal: Blood (2012)
Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.
Authors: Gabriela R. Rossi, Caio Max S. Rocha Lima, Jeffrey M Hardacre, Mary Frances Mulcahy, Mark S. Talamonti, Jennifer Carrie Obel, Howard Safran, Heinz-Josef Lenz, E. Gabriela Chiorean, Nicholas N. Vahanian, Charles J. Link
Journal: Journal of Clinical Oncology (2014)

3029 Background: Algenpantucel-L immunotherapy consists of allogeneic pancreatic cancer cells that have been genetically modified to express the carbohydrate α(1,3)Gal, to which humans have an inherent pre-existing immunity. It is αGal that is primarily responsible for the hyperacute rejection of foreign tissue via this potent immune defense mechanism in humans. Algenpantucel-L leverages this mechanism to educate the immune system towards components of the patients’ own tumor cells. Calreticulin is a calcium-binding chaperone protein that functions in the immune response by folding major histocompatibility complex (MHC) class I molecules and influencing antigen presentation to cytotoxic T cells. In pre-clinical models, drugs that induce cell surface CALR confer enhanced tumor protection. Components of algenpantucel-L express cell surface CALR. Methods: An open-label, 71 patient multicenter phase II study evaluating algenpantucel-L plus standard of care gemcitabine with 5-FU-XRT for resected pancreatic cancer was conducted. Endpoints included DFS at 1 year, OS, and immunologic analysis. Evaluable patients (n=64) were tested for the induction of anti-CALR Ab by ELISA. Increased titers greater than 20% relative to baseline were considered significant (p<0.001). Results: The study reached its endpoint at 1 year with DFS of 62% and OS of 86%. Thirty-one of 64 patients (48%) had increased anti-CALR Ab. Patients responding with an increase in anti-CALR Ab had a median OS of 35.8 months compared to 19.2 months for patients without an increase. The positive correlation between increased anti-CALR Ab and improved median OS was statistically significant (p=0.03). Conclusions: This study of algenpantucel-L with SOC for resected pancreatic cancer compared favorably to historical controls. Induction of anti-CALR Ab after therapy correlates with improved survival. Immunological monitoring of algenpantucel-L immunotherapy with this biomarker is feasible and might predict patient response to therapy. Follow up studies are in progress in a multi-institutional, phase III study which recently completed enrollment. Clinical trial information: NCT00569387.
Insight into Rhinovirus-Induced Asthma Exacerbation Using High-Throughput Immunosequencing of B-Cell Repertoires
Authors: Yu-Chang Bryan Wu, Aaron M. Rosenfeld, Nadine Upton, Jaideep Dhariwal, Uri Hershberg, David Kipling, Sebastian L. Johnston, Hannah J. Gould
Journal: Journal of Allergy and Clinical Immunology (2017)
ARRY-429520, a KSP Inhibitor with Efficacy in Animal Models of Solid and Liquid Tumors.
Authors: Rich Woessner, Chris Corrette, Shelley Allen, Jeremy Hans, Qian Zhao, Tom Aicher, Joe Lyssikatos, John Robinson, Greg Poch, Laura Hayter, April Cox, Patrice Lee, James Winkler, Kevin Koch, Eli Wallace
Journal: Blood (2006)
Neoadjuvant therapy with oxaliplatin (OXA) and 5-fluorouracil (5FU) continuous infusion (CI) combined with radiotherapy (RT)in rectal cancer: First results of the Bologna phase II study
Authors: C. Pinto, A. L. Gentile, B. Iacopino, S. Neri, G. Ugolini, F. Minni, C. Ceccarelli, G. N. Martinelli, B. Cola, A. Martoni
Journal: Journal of Clinical Oncology (2004)

3557 Background: The aim of this study was to assess 1) the impact of preoperative RT combined with OXA/5FU CI chemotherapy (CT) on tumour response, sphincter preservation and disease control in rectal cancer; 2) the correlation between biopathological factors and therapy response. Methods: Pts entering the study had histologically-proven rectal adenocarcinoma and stage uT3-T4 N-/+ or uT2 N-/+ with inferior location (<5 cm from the anal margin). CT consisted of a weekly schedule of OXA 60 mg/m2 IV for 6 times and 5FU 225 mg/m2/die CI IV d 1–38. RT was started the same day as CT. RT was delivered up to a dose of 50.4 Gy in daily fractions of 1.8 Gy (45 Gy in 25 fractions + a boost of 5.4 Gy in 3 fractions). Rectal surgery with TME was performed 6–8 weeks after the end of neoadjuvant treatment. 8 courses of adjuvant CT with LV5FU2 (de Gramont regimen) were given after surgery. The pathological examination of pre-treatment biopsy and operative specimen considered the immunohistochemical determination of Ki67, p53, bcl2, TS, EGFR, MLH1 and MSH2. Results: 26 pts were accrued between January 2002 and December 2003. The pt characteristics were: 18 men and 8 women; median age 64 years (41–82); median Karnofsky PS 100 (70–100); stage: 2 uT2N-M0, 1 uT2N+M0, 8 uT3N-M0, 12 uT3N+M0, 1 uT4N-M0, 2 uT4N+M0. So far 21 pts have completed the neoadjuvant therapy and surgery (median follow-up 10 months). No grade 4 toxicity was observed, while grade 3 toxicity was: neutropenia 4.8%, thrombocytopenia 4.8%, transaminases increase 4.8%, neurotoxicity 4.8%, diarrhoea 14.3%, epithelitis 4.8%. Pathological downstaging occurred in 12 pts (57.1%), including 3 pT0N0 and 8 pTmicN0. The median value of pathological determination in pre-treatment biopsy and the operative specimens was, respectively: Ki67 8% and 34%; p53 41% and 35%; TS 15% and 10%; MLH1 86% and 72%; MSH2 79% and 53%. In pT0N0 and pTmicN0 pts the biopsy media value of TS was 3.4% and MSH2 94.8%. Conclusions: The early results indicate that 1) this neoadjuvant treatment is active (52.4% pT0N0 + pTmicN0) and well-tolerated; 2) major pathological responses were observed in tumours with a low TS and a high MSH2. No significant financial relationships to disclose.
Rituximab in Neuromyelitis Optica Spectrum Disorders
Authors: Su-Hyun Kim, Ho Jin Kim
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
ANGI-02. NEW PERICYTES IN GLIOBLASTOMA (GBM) BLOOD-VESSELS ORIGINATE FROM A PREVIOUSLY UNRECOGNIZED, PERICYTE PROGENITOR-LIKE CELL
Authors: Rainer Glass, Joerg-Christian Tonn, Michael Synowitz, Verdon Taylor, Roland Kaelin
Journal: Neuro-Oncology (2016)

GBM is characterized by an exorbitant neo-vascularization and pericytes play a pivotal role in regulating tumor-vessel permeability and stability. Previous studies suggested that newly generated pericytes derive from mitotically active, mature pericytes, which can be identified by the expression of markers including PDGFR-B, NG2, desmin or CD146. Using a newly established transgenic lineage-tracing model (for conditional and timed recombination of nestin-expressing cells) we show that mature pericytes largely originate from marker-negative cells. In this orthotopic glioma model we studied pericyte development over a time-course. Throughout tumor growth recombined cells expanded in the tumor mass and labelling-experiments with different thymidine-analogues revealed their continuous proliferation. Strikingly, the vast majority of recombined cells in early gliomagenesis was negative for all pericyte-markers investigated (78% of all recombined cells did not express any marker), but the recombined cells acquired pericyte markers at later stages of tumor expansion (81% PDGFR-B-, 76% NG2-, 74% desmin- and 84% CD146-positive recombined cells were observed). Combinatorial immunofluorescence labeling showed that mature pericytes simultaneously express multiple markers. Using this model we were able to lineage-trace a large part of all intra-tumoral pericytes. This suggests that a very substantial number of newly generated pericytes derive from nestin-positive, PDGFR-B-, NG2-, desmin-, CD146-negative cells. Lineage-tracing experiments in bone-marrow chimeric glioma models and in the (tumor-free) developing brain indicated that pericyte-generating, marker-negative cells are endogenous to the brain. Electron microscopy studies corroborated the pericyte identity of the cells traced in our model. All in all, we provide an entirely new view on the generation of pericytes in pathological neo-angiogenesis. Our data firmly indicate that new pericytes origin, to a large extent, from a previously unrecognized immature pericyte. These newly discovered pericyte-progenitor-like cells may offer a new target to tackle tumor angiogenesis at the root.
Impaired Wnt-Pathway Signalling and Reduced Expression of Senescence-Associated Markers in Bone Marrow Mesenchymal Stem Cells of Patients with Myelodysplastic Syndromes
Authors: Konstantia I. Pavlaki, Maria-Christina Kastrinaki, Aristea Batsali, Anthi Demetriadou, Maria Velegraki, Irene Mavroudi, Michael Klontzas, Anna Psaraki, Maria Psyllaki, Charalampos Pontikoglou, Helen A. Papadaki
Journal: Blood (2011)
Predictors of Adverse and Systemic Reactions Associated with Oral Immunotherapy to Peanut: A Six-Year Experience
Authors: Tamar N. Rubin, Sagar Patel, Jason O. Lee, Louis M. Mendelson, Glenda Nouman, Janina Gilo-Tomkins, Charles E. Johnson, Rachel Powell, Jeffrey M. Factor
Journal: Journal of Allergy and Clinical Immunology (2017)
P07.01 18F-fluordesoxyglucose positron emission tomography (FDG-PET) for the detection of the primary lesion in brain metastasis (BM) patients with cancer of unknown primary site (CUPS)
Authors: F. Wolpert, H. Leske, A. S. Berghoff, E. J. Rushing, N. Andratschke, L. Regli, R. Stupp, P. Kaufmann, M. Preusser, M. Weller
Journal: Neuro-Oncology (2016)

Abstract In 30% of patients with brain metastasis (BM), BM are the first clinical manifestation of systemic malignancy, referred to as BM from cancer of unknown primary site (BM-CUPS). The value of F-fluordesoxyglucose positron emission tomography (FDG-PET)/CT in the work-up of BM-CUPS patients remains to be defined. We screened 566 patients operated for BM at the University Hospital Zurich between 2004 and 2014 and identified 127 BM-CUPS patients. Two validation cohorts (n=100 and 120 patients) from independent centers were available. FDG-PET/CT was not superior to CT in localizing the primary lesion as CT (FDG-PET/CT: 73/78, 93.6%; CT: n=70/78, 89.7%; p=0.25, McNemar’s test). Thirty-six of 64 patients (56.3%) showed the same result in spotting the primary tumor and other extracranial lesions. FDG-PET/CT identified additional lesions suspicious for extracranial metastases in 28 patients (43.7%). The graded prognostic assessment (GPA) score was determined post-hoc to objectify clinical relevance of additional findings. Information from CT alone or FDG-PET/CT was used to assess extracranial metastases. Median GPA was 3 for CT vs. 2.5 for PET/CT (p= 3.8x10), resulting in a predicted survival of 5.3 vs. 3.8 months (p= 6.1x10; Wilcoxon’s test). Sensitivity of CT and FDG-PET/CT and staging capabilities were comparable in all cohorts. FDG-PET/CT shows similar sensitivity to detect the primary tumor in BM-CUPS patients as CT, but improves the accuracy of staging. GPA scores and predicted survival differ significantly when calculated based on CT versus FDG-PET/CT. FDG-PET/CT should be prioritized for planning the diagnostic algorithm of BM-CUPS patients and redundant CT imaging should be avoided. Further, randomized trials on BM patients should consider stratification for the respective staging methods when employing GPA scores.
Indoor allergen and pollution exposure are not associated with higher prescribed treatment step in urban children with persistent asthma
Authors: Torie L. Grant, Meredith C. McCormack, Michelle Newman, Susan L. Balcer-Whaley, Jean Curtin-Brosnan, Erica Williams, Suzanne L. Rossi, Elizabeth Matsui
Journal: Journal of Allergy and Clinical Immunology (2017)
EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma
Authors: M. van den Bent, T. Gorlia, M. Bendszus, F. Sahm, J. Domont, A. Idbaih, M. Platten, M. Weller, V. Golfoinopoulos, W. Wick
Journal: Neuro-Oncology (2016)
Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts)
Authors: J. Alcaide-Garcia, T. Pereda, E. Perez-Ruiz, F. Rivas, I. Zarcos Pedrinaci, R. Villatoro, D. Perez, A. Rueda
Journal: Annals of Oncology (2016)
SMO mutations role in malignant pleural mesothelioma: a negative prognostic factor, but possible new target?
Authors: C. Proto, M. Ganzinelli, L. Botta, M. Tiseo, G. Pasello, A. Fabbri, G. Lo Russo, A. Trama, M. Imbimbo, M. Vitali, M. Macerelli, N. Zilembo, R. Gallucci, A. Brissa, M. Platania, N. Zaffaroni, M.S. Serafini, F. De Braud, M. Garassino, D. Signorelli
Journal: Annals of Oncology (2016)